The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
MDR Tuberculosis — Critical Steps for Prevention and Control
Open accessAbstract
ultidrug-resistant (MDR) tuberculosis is defined as disease caused by strains of Mycobacterium tuberculosis that are at least resistant to treatment with isoniazid and rifampicin; extensively drug-resistant (XDR) tuberculosis refers to disease caused by multidrug-resistant strains that are also resistant to treatment with any fluoroquinolone and any of the injectable drugs used in treatment with second-line anti-tuberculosis drugs (amikacin, capreomycin, and kanamycin).MDR tuberculosis and XDR tuberculosis are serious threats to the progress that has been made in the control of tuberculosis worldwide over the past decade.1,2 In 2008, an estimated 440,000 cases of MDR tuberculosis emerged globally.1 India and China carry the greatest estimated burden of MDR tuberculosis, together accounting for almost 50% of the world's total cases.More than three quarters of the estimated cases of MDR tuberculosis occur in previously untreated patients.The proportion of MDR cases among new cases and previously treated cases of tuberculosis reported globally from 1994 through 2009 ranged from 0 to 28.3% and from 0 to 61.6%, respectively (Fig. 1).The highest proportions of MDR cases, and the most severe drug-resistance patterns, appear in the countries of the former Soviet Union.By 2009, a total of 58 countries had reported at least one case of XDR tuberculosis.In eight countries, reported cases of XDR tuberculosis account for more than 10% of all cases of MDR tuberculosis, and six of these countries were part of the former Soviet Union.By far the largest number of cases of XDR tuberculosis has been reported from South Africa (10.5% of all cases of MDR tuberculosis in that country), owing to rapid spread among people infected with the human immunodeficiency virus (HIV).National programs are failing to diagnose and treat MDR tuberculosis.Globally, just under 30,000 cases of MDR tuberculosis were reported to the World Health Organization (WHO) in 2008 (7% of the estimated total), of which less than one fifth were managed according to international guidelines.The vast majority of the remaining cases probably are not diagnosed or, if diagnosed, are mismanaged.This problem remains despite the evidence that management of MDR tuberculosis is cost-effective 3 and that treatment of MDR tuberculosis, and even treatment of XDR tuberculosis, is feasible in persons who are not infected with HIV.4,5 In some countries, the incidence of tuberculosis is rising, and the incidence of MDR tuberculosis appears to be rising even faster (e.g., in Botswana and South Korea).6 However, in Estonia, Hong Kong, the United States, and Orel and Tomsk Oblasts (in the Russian Federation), the incidence of tuberculosis is falling, and the incidence of MDR tuberculosis appears to be falling even faster.1,6 This trend is
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
All for universal health coverage
Garrett, L., Chowdhury, A. M. R., & Pablos-Méndez, A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61503-8 · Cited by 142
Cited by
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Self-citationTowards tuberculosis elimination: an action framework for low-incidence countries
Lönnroth, K., Migliori, G. B., Abubakar, I., D'Ambrosio, L., de Vries, G., Diel, R., Douglas, P., Falzon, D., Gaudreau, M.-A., Goletti, D., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00214014 · Cited by 778
Self-citationZumla, A., Raviglione, M., Hafner, R., & Fordham von Reyn, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1200894 · Cited by 698
Self-citationNational Survey of Drug-Resistant Tuberculosis in China
Zhao, Y., Xu, S., Wang, L., Chin, D. P., Wang, S., Jiang, G., Xia, H., Zhou, Y., Li, Q., Ou, X., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108789 · Cited by 631
Scaling up interventions to achieve global tuberculosis control: progress and new developments
Raviglione, M., Marais, B., Floyd, K., Lönnroth, K., Getahun, H., Migliori, G. B., Harries, A. D., Nunn, P., Lienhardt, C., Graham, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60727-2 · Cited by 340
Self-citation
Metadata
- Authors
- Nathanson, E., Nunn, P., Uplekar, M., Floyd, K., Jaramillo, E., Lönnroth, K., Weil, D., & Raviglione, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-09
- Volume
- 363
- Issue
- 11
- Pages
- 1050-1058
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2105010248
- Cited by
- 189
- References
- 2
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MDR Tuberculosis — Critical Steps for Prevention and Control. https://app.cochat.ai/papers/10.1056/nejmra0908076
- The paper
- Nathanson, E., Nunn, P., Uplekar, M., Floyd, K., Jaramillo, E., Lönnroth, K., Weil, D., & Raviglione, M. (2010). MDR Tuberculosis — Critical Steps for Prevention and Control. New England Journal of Medicine. https://doi.org/10.1056/nejmra0908076
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.